Key Markets Update

NZX/ASX Announcement 20 May 2024 TruScreen – Key Markets Update Highlights • TruScreen installed in major hospital in Jiangsu, China • Collaboration with PT Mursmedic in Indonesia with product registration in progress • MOH Uzbekistan evaluating TruScreen for national screening program • TruScreen partnering with Phillips Pharma for expansion in Kenya, Nigeria, Uganda, Ghana and Tanzania • Further progress in Vietnam, Saudi Arabia and Mexico TruScreen Group Limited (NZX/ASX:TRU) is pleased to provide an update of its key markets and key target markets. TruScreen continues to make steady progress in its global commercialisation. China continues to be TruScreen’s key focus, however there are some exciting opportunities in a number of new markets as outlined below. China Number of Women of Screening Age: 476,599,793* In April, TruScreen’s distributor in China, Beijing Siweixiangtai Tech Ltd. Co (SWXT), commenced a major initiative in Jiangsu province, located in Eastern China with a population of 85 million people. TruScreen was installed and key staff trained in the Affiliated Hospital of Nantong University, a major hospital in North Jiangsu. The hospital’s head of Obstetrics and Gynaecology is a Key Opinion Leader in this region. SWXT’s local distributor estimates that this hospital will achieve a 1,000 SUS per month pull through, bringing it into the top 5 TruScreen sites globally. SWXT reinforced the inclusion of TruScreen in the Chinese Society of Colposcopy and Cervical Pathology (CSCCP) guidelines by sponsoring their annual conference held in Tianjin on 10 to 12 May 2024. The conference was attended by more than 1,000 gynaecologists from around the country. The sponsorship is an extension of SWXT’s work with CSCCP to ‘normalise’ the use of TruScreen in cervical cancer screening. Sales of our disposable Single Use Sensors (SUS) in China continue to grow, with monthly sales in April growing 3.6% month on month. We have also completed our price review in China to reflect our increased cost pressures. Indonesia Number of Women of Screening Age: 95,961,293* TruScreen, with the support of the local Austrade office, is making strides in Indonesia. Indonesia sees over 36,000 women diagnosed with cervical cancer annually. PT Mursmedic (https://mursmedic.com/) has commenced the product registration process for TruScreen in Indonesia. Based in Jakarta, Mursmedic’s other clients include a suite of major medical device manufacturers such as Fisher and Paykel Healthcare, Cook, Nanosonics, Stryker and ThermoFisher Scientific. A key reference site in Jakarta has been identified and installation will occur as soon as registration is completed. Uzbekistan Number of Women of Screening Age: 11,617,411* The Ministry of Health in Uzbekistan is evaluating TruScreen as a technology to deliver a part of the Uzbekistan National Screening Solution for Cervical Cancer. This program is a first for Uzbekistan and being selected would be a transformative opportunity for TruScreen, not just in Uzbekistan but also to serve as a reference site for other neighbouring Central Asian countries. Kenya Number of Women of Screening Age: 17,723,012* TruScreen is currently in the process of registration in Kenya through our logistics partner, Phillips Pharma Group ( https://phillipspharma.group/ ). Phillips Pharma is one of the most trusted partners in Sub Saharan Africa supporting many of the major multinational Pharma and Medical Device companies, as well as Government and NGO clients. Leveraging our proven capability as a screening solution for women in Zimbabwe, TruScreen will partner with Phillips Pharma first in Kenya, and then to expand to other countries within their footprint, including Nigeria, Uganda, Ghana and Tanzania. Mexico Number of Women of Screening Age: 45,983,174* TruScreen has recently gained regulatory approval (Cofepris) for TruScreen to be used as a cervical cancer screening system for public hospitals. Our distributor Sunbird S.A de C.V is leveraging this approval to gain access to key influencing hospitals in the capital and as a result we have this month shipped 9 devices to Mexico. Vietnam Number of Women of Screening Age: 35,887,201* Since our inclusion in the Vietnamese Ministry of Health Technical List, significant strides have been made to streamline the approval process for our medical technology. Our distributor, Gorton Health Services (GHS), has targeted approval in 64 major public hospitals. GHS is supporting this initiative to drive the adoption in these targeted hospitals by showcasing TruScreen at the Vietnam National Gynaecologic Conference on May 24th. Installation into the first key reference sites will commence mid to late 2024, with a projected peak installation into hospitals in 2025. Saudi Arabia: Number of Women of Screening Age: 10,994,061* Following early success in the private health system, including gaining private health insurance reimbursement and installation in key reference centres, our distributor Bettalife is working to have TruScreen accepted into the public healthcare system. Similar to Uzbekistan, TruScreen is being considered as a component, alongside other technologies, for the National Screening solution for the 7 million women under public health care in Saudi Arabia. Poland Number of Women of Screening Age: 13,036,977* Poland continues to face significant challenges with cervical cancer. TruScreen is working with the Mother and Child Institute and has identified both private and public hospitals as the first to move from Liquid Based Cytology to TruScreen. TruScreen is shortly entering the hospital validation phase with commercial sales following the successful completion of this evaluation. North Macedonia Number of Women of Screening Age: 719,627* TruScreen is currently undergoing evaluation by a local distributor who operates a Medical Clinic in North Macedonia. When successful, TruScreen will replace Pap Smear in the clinic. This clinic will serve as a base for demonstration and training for future customers in south eastern Europe. This potential partnership marks a significant milestone as it would be TruScreen's first partner who is both a distributor and a key reference centre. *All population figures are for women aged 15-64 years as detailed in the World Fact Book : https://www.cia.gov/the-world-factbook/ Martin Dillon, CEO of TruScreen said “I am excited with the opportunities that TruScreen now has. Many of these markets have taken us many years to gain meaningful access and TruScreen is now gaining momentum which should deliver much improved results in the year ahead.” This announcement has been approved by the Board. ENDS For more information, visit www.truscreen.com or contact: Marty Dillion Chief Executive Officer martindillon@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com